TherapeuticsMD
TXMD
137 hedge funds and large institutions have $1.05B invested in TherapeuticsMD in 2016 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 40 reducing their positions, and 12 closing their positions.
1,095% more call options, than puts
Call options by funds: $4.89M | Put options by funds: $409K
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
15% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 40
11% more funds holding
Funds holding: 123 → 137 (+14)
0.05% less ownership
Funds ownership: 1.63% → 1.58% (-0.05%)
23% less capital invested
Capital invested by funds: $1.36B → $1.05B (-$309M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.85M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$5.13M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$3.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$74M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$9.68M |
| 3 |
GH
GAM Holding
Zurich,
Switzerland
|
-$6.53M |
| 4 |
JP Morgan Chase
New York
|
-$5.45M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$4.27M |
TXMD Hedge Fund Activity: Q3 2016 in Review
137 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2016, worth a combined $1.05B — down 23% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TXMD positions and 12 closed out — a net gain of 14 holders — while 46 added to existing stakes and 40 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $13.1M. The largest seller was Wellington Management Group, cutting an estimated $74M.
- 137 institutional investors held TherapeuticsMD (TXMD) as of Q3 2016, up from 123 in Q2 2016.
- Funds reported $1.05B of TherapeuticsMD stock for Q3 2016, down 23% quarter-over-quarter.
- 26 funds opened new TherapeuticsMD positions in Q3 2016 and 12 closed out, a net change of +14 holders.
- The largest TherapeuticsMD buyer in Q3 2016 was T. Rowe Price Associates, an estimated $13.1M added.
- The largest TherapeuticsMD seller in Q3 2016 was Wellington Management Group, an estimated $74M sold.
Based on aggregated 13F filings for Q3 2016.